Report of Foreign Issuer (6-k)
21 May 2019 - 6:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: May 2019
Commission
file number: 001-36578
ENLIVEX
THERAPEUTICS LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
Financial
Statements
The
unaudited consolidated financial statements for Enlivex Therapeutics Ltd. (“Enlivex”), a company organized under the
laws of the State of Israel, as of and for the three months ended March 31, 2019 and 2018, and the Operating and Financial Review
and Prospects of Enlivex for the corresponding periods are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report
on Form 6-K and incorporated by reference herein.
Exhibit
No.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
May 20, 2019
|
Enlivex
Therapeutics Ltd.
|
|
(Registrant)
|
|
|
|
By:
|
/s/
Shai Novik
|
|
Name:
Title:
|
Shai
Novik
Executive Chairman
|
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Jul 2023 to Jul 2024